Hosted by Drug Dealin Pod · 🇺🇸 US · EN · 10 episodes
Established thought leaders with verified media credentials.
Ever wondered what's really happening behind the scenes in the biotech and pharmaceutical industry? Drug Dealin' pulls back the curtain. Co-hosts Shivu Sharma and Kenny Lalwani, two seasoned BioPharma professionals, offer unparalleled insider insights, dissecting the latest news, trends, and catalysts. Each episode features in-depth discussions and interviews with industry luminaries, giving you honest and unvarnished perspectives you won't find anywhere else.
Drug Dealin Pod hosts Drug Dealin, a science show with 10 episodes published.
SUMMARY In this episode, Shivu and Kenny discuss how you as a caregiver or patient can use public resources like clinicaltrials.gov and Large Language Models (LLMs) like ChatGPT to discover the latest treatment options f
Summary In this episode, Shivu and Kenny review their predictions for 2025 and make new predictions for 2026. They discuss trends in mergers and acquisitions, market performance, the impact of AI in drug development, and
SUMMARY In this deep dive into biopharma M&A trends, Shivu and Kenny analyze 10 years of acquisition data from major pharma players, revealing rising deal volumes and the increasing prevalence of Contingent Value Rights
SUMMARY: In this episode, Shivu and Kenny discuss the recent developments surrounding Replimune and its interactions with the FDA. They explore the implications of leadership changes at the FDA, the importance of patient
Summary: In this episode we chat with Joe McCann, CEO of Slingshot Insights. Joe estimates he has done somewhere between 5-10K calls interviewing physicians. In today's episode we tap into his insights on how to get more
Summary: In this episode, Shivu and Kenny delve into the evolving landscape of GLP-1 drugs, particularly focusing on the recent advancements in oral formulations and their potential applications beyond diabetes and obesi
A conversation with biotech leader, Sujal Shah, former CEO of CymaBay Therapeutics about his company's story arc, leadership, resilience, and building a biotech company in the face of adversity. Questions?: drugdealinpod
A conversation with biotech leader, Sujal Shah, former CEO of CymaBay Therapeutics about his company's story arc, leadership, resilience, and building a biotech company in the face of adversity. Questions?: drugdealinpod
Kenny and Shivu each cook up three predictions for Biopharma in 2025 NOTE: This episode was recorded on January 10th, 2025 Have feedback for us? Leave a comment or email us at DrugDealinPod@gmail.com Disclaimer: The view
In this episode, we unpack, examine, and debunk the public perception that drug companies intentionally do not pursue curative therapies, because it is financially less beneficial to them. We speak from our own experienc
What is Drug Dealin' going to be about? How are the Drug Dealin' hosts and should you listen to us? What type of content can you expect from this show? Disclaimer: The views and opinions expressed in this podcast are for
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Drug Dealin has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their science audience.
Drug Dealin is hosted by Drug Dealin Pod. The show is categorised under science (life) and has published 10 episodes.
Drug Dealin has published 10 episodes.
Drug Dealin regularly covers science, life. It sits in the science category, with a life focus.
Drug Dealin is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Drug Dealin hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Drug Dealin average 79 minutes, giving guests a long-form format with plenty of time to expand on their expertise.
Our data rates Drug Dealin's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched yesterday.
